Clinical

The treatment landscape for multiple myeloma has shifted since European Organisation for Research and Treatment of Cancer Quality of Life Multiple Myeloma Questionnaire (EORTC QLQ-MY20) was first developed in 1996.

A second study will evaluate the treatment and financial burden and quality of life of a program of subcutaneous daratumumab administered at home.

Randomized controlled trials had lower rates of success, but microbiota restoration still out-performed antibiotics.

The panelists provide their final thoughts regarding disparities in women’s health.

Misdiagnosis was common in these patients, and mean time to diagnosis was around 5 years.

Project CARA, a perinatal substance exposure clinic, has implemented a contingency management program that targets appointment attendance for patients with any use disorder, regardless of substance or urine drug screen results.

However, overall fertility rates of patients with psoriasis were similar to national fertility trends, authors found.

The study also highlighted disparities in accurate diagnosis of myelodysplastic syndromes (MDS).

The treatment landscape for HIV is discussed by a panel led by Dr Welch.

Key opinion leaders discuss the influence of guideline-directed therapy in the treatment of patients with HIV.

Both genera and regional anesthesia can be safely used in patients with pulmonary arterial hypertension (PAH).

The 68-year-old patient had multiple myeloma and breast cancer.

The incidence rate of melanoma in situ (MIS) has sharply risen since 1975.

Vaccine hesitancy is a significant barrier to optimal RSV vaccine rollout.

Experts discuss strategies to prepare for the oncoming respiratory diseases season.

Dr Filer highlights the considerations for the rollout of new RSV vaccines.

The pathophysiology and treatment of active and inactive MS are explored.

Ryan Haumschild, PharmD, MS, MBA, leads a discussion around the epidemiology of multiple sclerosis.

This study evaluates the impact of Choosing Wisely–based interventions on antibiotic prescribing for viral respiratory tract infections in a real-world safety-net setting.

Panelists provided a wide-ranging view of the current avenues being investigated to optimize the treatment of chronic lymphocytic leukemia (CLL), including minimal residual disease assessment, combination regimens, and chimeric antigen receptor T-cell therapy.

The most exciting treatment for inherited retinal disease was approved in 2017, but there are many novel treatments in phase 2 or phase 3 trials at this point, said Byron L. Lam, MD, professor of ophthalmology, University of Miami Miller School of Medicine's Bascom Palmer Eye Institute.

The late-breaking oral session at the European Hematology Association (EHA) 2023 Congress featured newly emerged data from abstracts submitted after the deadline, including outcomes from trials in polycythemia vera, acute myeloid leukemia, and more.

Results are based on a series of surveys completed by 17 experts.

Patients with the rare disease typically present with hypertrophic cardiomyopathy and muscular hypotonia before the age of 1.

Findings are based on a case-control study carried out in Brazil.

The first phase 3 results from the CARTITUDE-4 trial of ciltacabtagene autoleucel (cilta-cel) vs standard of care in lenalidomide-refractory multiple myeloma (MM) demonstrated the former’s convincing superiority in several key outcomes.

James F. Howard Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill, explains how nerve and muscle signaling in the neuromuscular junction go awry in myasthenia gravis.

Skin rashes are common among patients who complete hematopoietic cell transplantation (HCT).

Tycel Phillips, MD, hematologist-oncologist at City of Hope in Duarte, CA, discussed the utility of epcoritamab in diffuse large B-cell lymphoma (DLBCL) and the potential impacts the bispecific antibody's recent approval will have in the community oncology setting.

Investigators evaluated long-term outcomes among individuals who have eosinophilic esophagitis (EoE) and initiated first-line treatment with a food elimination diet after experiencing remission following stoppage of proton pump inhibitor monotherapy.